RDY 353 (Rivastigmine tartrate 3 mg)
Pill imprint RDY 353 has been identified as Rivastigmine tartrate 3 mg.
Rivastigmine is used in the treatment of alzheimer's disease; parkinson's disease; lewy body dementia and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 3 mg is not a controlled substance under the Controlled Substance Act (CSA).
More about rivastigmine
- Rivastigmine patch
- Rivastigmine solution
- Rivastigmine transdermal
- Rivastigmine (Advanced Reading)
- Rivastigmine Transdermal (Advanced Reading)
- Other brands: Exelon
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2015 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.